NCT06490744 Evolution of Respiratory Function in Lung Transplant Patients With Moderate to Severe Covid-19 Infection
| NCT ID | NCT06490744 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | COVID-19 Respiratory Infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 75 participants |
| Start Date | 2023-09-04 |
| Primary Completion | 2024-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 75 participants in total. It began in 2023-09-04 with a primary completion date of 2024-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The SARS-Cov-2 infection pandemic has caused a large number of acute respiratory failures and deaths across the world. Certain factors have been identified as associated with a higher risk of developing a severe form and dying. Immunosuppression has been identified as a risk factor for progressing to a severe form. Lung transplant patients were particularly vulnerable during this period, with a high frequency of respiratory compromise, sometimes progressing towards acute respiratory distress syndrome and, at a later stage, towards fibrotic forms. The impact of the infection on the immunological status of the patient and on the tolerance of the transplant have been little studied. The various treatments implemented during the pandemic have rapidly evolved (immunotherapy, vaccination, convalescent plasma transfusion, etc.) which may have modulated this risk. The evolution of respiratory function may be linked to the respiratory infection itself, or to the severity of respiratory damage during the infection. It is therefore relevant to compare patients with a moderate form of COVID-19 (non-intubated patients) to patients with severe forms, requiring invasive ventilation in intensive care. The evolution of respiratory function after infection has not yet been studied.
Eligibility Criteria
Inclusion Criteria: * Adult patient * Lung transplant patient (monopulmonary or bipulmonary) * Covid diagnosed by RT-PCR between March 1, 2020 and December 31, 2022 * Hospitalization at the University Hospitals of Strasbourg for COVID-19 * Patient followed in the context of their lung transplant at the University Hospitals of Strasbourg * Absence of written opposition in the subject's medical file to the reuse of their data for scientific research purposes. Exclusion Criteria: * Subject having expressed his opposition to the reuse of his data for scientific research purposes.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06490744 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying COVID-19 Respiratory Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06490744 currently recruiting?
Yes, NCT06490744 is actively recruiting participants. Contact the research team at charlesambroise.tacquard@chru-strasbourg.fr for enrollment information.
Where is the NCT06490744 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT06490744 clinical trial?
NCT06490744 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 75 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.